TVTX — Travere Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapNeutral

Annual cashflow statement for Travere Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-180	-278	-111	-322	-25.5
Depreciation
Non-Cash Items	58.7	58.2	-182	104	16.6
Discontinued Operations
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	80	0.904	-25.5	-63	-14
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Cash from Operating Activities	-14.8	-186	-280	-237	37.8
Capital Expenditures	-24.2	-28.6	-42.3	-101	-58.2
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-113	-4	98	201	86
Acquisition of Business
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-138	-32.6	55.8	99.3	27.9
Financing Cash Flow Items	-6.09	-11.5	-0.316	0.232	0.692
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	232	118	219	139	-33.5
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	81	-104	-3.51	0.359	34.5